Erratum to “Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update” (Canadian Journal of Diabetes (2016) 40(6) (484–486) (S1499267116305925) (10.1016/j.jcjd.2016.09.003));Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update

Canadian Journal of Diabetes

Volumn 40, Issue 6, 2016, Pages 484-486

  Booth, Gillian ^a   Lipscombe, Lorraine ^a   Butalia, Sonia ^a   Dasgupta, Kaberi ^a   Eurich, Dean ^a   Goldenberg, Ronald ^a   Khan, Nadia ^a   MacCallum, Lori ^a   Shah, Baiju ^a   Simpson, Scot ^a   Houlden, Robyn L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; EMPAGLIFLOZIN; HEMOGLOBIN A1C; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; PIG INSULIN; PLACEBO; SHORT ACTING INSULIN; SULFONYLUREA; ANTIDIABETIC AGENT;

ACUTE CORONARY SYNDROME; ACUTE DISEASE; ADVERSE OUTCOME; ANTIDIABETIC ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHOLELITHIASIS; CLINICAL OUTCOME; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; DIABETIC CARDIOMYOPATHY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED PRACTICE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LIFESTYLE MODIFICATION; MACROALBUMINURIA; MAXIMUM TOLERATED DOSE; MORTALITY RISK; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; PROGNOSIS; STANDARDS;

DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; HUMANS; HYPOGLYCEMIC AGENTS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS;

EID: 85002833256     PISSN: 14992671     EISSN: 23523840     Source Type: Journal    
DOI: 10.1016/j.jcjd.2017.01.006     Document Type: Erratum

References (14)

1. 1 Booth, G., Cheng, A.Y.Y., Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada: Methods. Can J Diabetes 37:Suppl. 1 (2013), S4–7.
2. 2 Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
3. 3 Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. for the; LEADER steering committee on behalf of the LEADER trial investigators N Engl J Med 375 (2016), 311–322.
4. 4 Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Pharmacologic management of type 2 diabetes: 2016 interim update. Can J Diabetes 40 (2016), 193–195.
5. 5 Fitchett, D., Zinman, B., Wanner, C., et al., EMPA-REG OUTCOME trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: Results of the EMPA-REG OUTCOME trial. Eur Heart J 37 (2016), 1526–1534.
6. 6 Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. for the; EMPA-REG OUTCOME investigators N Engl J Med 375 (2016), 323–334.
7. 7 Pfeffer, M.A., Claggett, B., Diaz, R., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
8. 8 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853.
9. 9 UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998), 854–865.
10. 10 Holman, R.R., Paul, S.K., Bethel, M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008), 1577–1589.
11. 11 Sumeet, R., Singh, S.R., Ahmad, F., et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: A meta-analysis. CMAJ 180 (2009), 385–397.
12. 12 Horvath, K., Jeitler, K., Berghold, A., et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus (review). Cochrane Database Syst Rev(2), 2007 CD005613.
13. 13 Monami, M., Marchionni, N., Mannucci, E., Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: A meta-analysis. Diabetes Res Clin Pract 81 (2008), 184–189.
14. 14 Manucci, E., Monami, M., Marchionni, N., Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: A meta-analysis. Diabetes Obes Metab 11 (2009), 53–59.